19.74
+0.03(+0.15%)
Currency In USD
| Previous Close | 19.71 |
| Open | 19.55 |
| Day High | 20.03 |
| Day Low | 19.38 |
| 52-Week High | 20.2 |
| 52-Week Low | 8.58 |
| Volume | 1.34M |
| Average Volume | 2.73M |
| Market Cap | 1.71B |
| PE | -5.48 |
| EPS | -3.6 |
| Moving Average 50 Days | 16.01 |
| Moving Average 200 Days | 13.25 |
| Change | 0.03 |
If you invested $1000 in Syndax Pharmaceuticals, Inc. (SNDX) since IPO date, it would be worth $1,644.58 as of December 04, 2025 at a share price of $19.735. Whereas If you bought $1000 worth of Syndax Pharmaceuticals, Inc. (SNDX) shares 5 years ago, it would be worth $803.22 as of December 04, 2025 at a share price of $19.735.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participat
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
GlobeNewswire Inc.
Nov 03, 2025 2:08 PM GMT
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along wit
Syndax Announces Participation in November Investor Conferences
GlobeNewswire Inc.
Oct 30, 2025 11:00 AM GMT
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as memb